Västra Hamnen: ChemoTech - Starting to move
Västra Hamnen Corporate Finance has released a research update on Scandiavian ChemoTech following its report for Q3 2018. We reiterate our fair value range of 18.20 - 26.70 SEK per share.· Treatments are picking up speed; 15 patients treated in September alone · Indian study results highly supportive of D-EECT protocol · CE mark delayed until 2019 Scandinavian ChemoTech AB (publ) recently presented its report for Q3 and the overall picture was one of progress. The company reported that the IQwave™ is being used to treat more patients and that more clinics have started evaluating